Vanda Pharmaceuticals Inc. Share Price Today: Live Updates & Key Insights
Vanda Pharmaceuticals Inc. share price today is $9.29, up 0%. The stock opened at $9.35 against the previous close of $9.29, with an intraday high of $9.5 and low of $9.1275.
Vanda Pharmaceuticals Inc. Share Price Chart
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. Share Price Performance
Vanda Pharmaceuticals Inc. Institutional Holdings
Vanda Pharmaceuticals Inc. Market Status
Vanda Pharmaceuticals Inc. Fundamentals
Market Cap 549.11 M
PB Ratio 1.7307
PE Ratio 0.0
Enterprise Value 315.03 M
Total Assets 488.95 M
Volume 1628589
Vanda Pharmaceuticals Inc. Company Financials
About Vanda Pharmaceuticals Inc. & investment objective
Company Information Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Organisation Biotechnology
Employees 533
Industry Biotechnology
CEO Dr. Mihael H. Polymeropoulos M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
